Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.

Nucleic-acid therapeutics articles from across Nature Portfolio Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds.

Scientists at The Wistar Institute have discovered how a key protein from the Epstein-Barr virus (EBV), EBNA-LP, ...

The variety of potentially useful dyes or haptenes available for fluorescent nucleic acid hybridization assays is far greater than what can be obtained from commercial sources 1,2. Since this ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

When the Empire State Building was constructed, its 102 stories rose above midtown one piece at a time, with each individual ...

Imagine if you could "print" a tiny skyscraper using DNA instead of steel. That’s what researchers at Columbia and Brookhaven ...

Malaria merozoite surface proteins (MSPs), are thought to have important roles in red blood cell (RBC) invasion and their exposure on the parasite surface makes them attractive vaccine candidates.

Exponential nucleic acid replication can occur isothermally in a prebiotically plausible setting that accumulates and simultaneously separates the strands of nucleic acids through evaporation-driven ...

The dynamic competition between negatively charged IDRs and nucleic acids can accelerate the target search processes for these proteins. When a protein encounters DNA or RNA, the electrostatic ...